Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
IC41 · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| IC41 | EXPERIMENTAL | 8 injections of 4 x 0.125mL |
| IC41-B-01/02 | EXPERIMENTAL | peptide dose 0.00 mg, polyarginine dose 2.00 mg |
| IC41-C-01/02 | EXPERIMENTAL | peptide dose: 5.00 mg, polyarginine dose: 0.00 mg |
| IC41-G-01/02 | EXPERIMENTAL | peptide dose: 2.50 mg, polyarginine dose: 1.25 mg |
| IC41-H-01/02 | EXPERIMENTAL | peptide dose: 2.50 mg, polyarginine dose: 2.00 mg |
| IC41-K-01/02 | EXPERIMENTAL | peptide dose: 5.00 mg, polyarginine dose: 2.00 mg |
| Name | Type | Description |
|---|---|---|
| IC41 | BIOLOGICAL | injection |
Inclusion Criteria: * Written informed consent obtained prior to study entry * Patients with chronic hepatitis C; genotype 1 * Treatment naive patients * Male and Female, 18 to 55 years * Presence of HLA-A2 marker * Mentally healthy * No clinically relevant pathological findings in any of the inves...
IC41 is an investigational therapeutic vaccine being developed for chronic hepatitis C. It is designed to treat patients with this viral infection. The drug is currently in clinical development and has completed Phase 2 trials, but it is not yet approved for use.
IC41 is being developed by Valneva SE, a biopharmaceutical company. Valneva's stock is traded under the ticker symbol VALN. The company is conducting clinical trials to evaluate the safety and efficacy of IC41 in patients with chronic hepatitis C.
IC41 is in Phase 2 clinical development. Two Phase 2 trials have been completed, with a total of 137 participants enrolled. The drug is still investigational and has not received regulatory approval for the treatment of chronic hepatitis C.
IC41 has been studied in two completed Phase 2 clinical trials. The first trial, NCT00601770, enrolled 71 participants and was conducted in Germany, Poland, and Romania. The second trial, NCT00602784, enrolled 66 participants. Both trials focused on chronic hepatitis C.
IC41 is classified as a monoclonal antibody in the available data. However, it is being studied as a therapeutic vaccine for chronic hepatitis C. The drug is administered to stimulate an immune response against the hepatitis C virus.